SCHEMBL4142269

SCHEMBL4142269

CN1CCN(c2ccc3nc(-c4ccc(-c5ncc(CO)cc5Cl)cc4)[nH]c3c2)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.60
SMN1; SMN2 Q16637 4/20 0.60
TOP1 P11387 3/20 0.60
TOP2A P11388 3/20 0.60
HPGD P15428 1/20 0.60
HSD17B10 Q99714 1/20 0.60
MEN1 O00255 2/20 0.58
MAPT P10636 2/20 0.58
BLM P54132 2/20 0.58
KMT2A Q03164 2/20 0.58
SLCO2B1 O94956 1/20 0.58
GLA P06280 1/20 0.58
RECQL P46063 1/20 0.58
BCL2L1 Q07817 1/20 0.58
SLCO1B3 Q9NPD5 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
SLCO1B1 Q9Y6L6 1/20 0.58
TERT O14746 5/20 0.52
KDM4E B2RXH2 2/20 0.51
GAA P10253 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4151233 0.91 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL4143484 0.91 SIRT2 (0.55) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL4139318 0.82 CBFB (0.54) TERTDGAT1SOAT1KCNH2BRD4
SCHEMBL4140020 0.79 MMP13 (0.52) ALDH1A1SMN1; SMN2HPGDHSD17B10MEN1
SCHEMBL4551767 0.79 SIRT2 (0.56) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL4139643 0.79 SCD (0.52)
SCHEMBL13741429 0.78 NPC1 (0.52) ALDH1A1SMN1; SMN2HPGDHSD17B10MEN1
SCHEMBL4140467 0.77 DGAT1 (0.57) DGAT1SOAT1KCNH2
SCHEMBL4146860 0.76 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL15252695 0.76 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2054405-B1 NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAE WOONG PHARMA (KR) 2013-09-18 EP claimed
US-20130217684-A1 NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2013-08-22 US claimed
US-20090209540-A1 Novel Biaryl Benzolmidazole Derivatives and Pharmaceutical Composition Comprising The Same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2009-08-20 US claimed
EP-2054405-A1 NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2009-05-06 EP claimed
WO-2008007900-A1 NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2008-01-17 WO claimed
US-8940769-B2 Biaryl benzoimidazole derivatives and pharmaceutical composition comprising the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-01-27 US disclosed
EP-2054405-B1 NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAE WOONG PHARMA (KR) 2013-09-18 EP disclosed
US-20130217684-A1 NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2013-08-22 US disclosed
US-8436022-B2 Biaryl benzolmidazole derivatives and pharmaceutical composition comprising the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2013-05-07 US disclosed
US-20090209540-A1 Novel Biaryl Benzolmidazole Derivatives and Pharmaceutical Composition Comprising The Same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2009-08-20 US disclosed
EP-2054405-A1 NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2009-05-06 EP disclosed
WO-2008007900-A1 NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209540-A1 Novel Biaryl Benzolmidazole Derivatives and Pharmaceutical Composition Comprising The Same TRPV1, TRPV3, TRPV5 ALDH1A1 2414/4885SMN1; SMN2 1780/4885TOP1 4507/4885
US-20130217684-A1 NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME TRPV1, TRPV3, TRPA1 ALDH1A1 3932/4885SMN1; SMN2 1877/4885TOP1 4457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.